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Abstract
During embryonic development, cells in an uncommitted pluripotent state undergo progressive
epigenetic changes that lock them into a final restrictive differentiated state. However, recent
advances have shown that not only is it possible for a fully differentiated cell to revert back to a
pluripotent state, a process called nuclear reprogramming, but also that differentiated cells can be
directly converted from one class into another without generating progenitor intermediates, a
process known as direct lineage conversion. In this review, we discuss recent progress made in direct
lineage reprogramming of differentiated cells into neurons and discuss some of the therapeutic
implications of the findings.
Introduction
During embryonic development, cells in an uncom-
mitted pluripotent state undergo progressive epigenetic
changes that lock them into a final differentiated state.
Famously, Conrad Hal Waddington likened this process
to a marble traveling down a downward slope and
ending up in one of the many valleys surrounded by
impassable hills [1]. This epigenetic landscape model has
often been used to explain the restrictive nature of the
differentiated cell state.
However, somatic cell nuclear transfer experiments,
cellular fusion experiments and, more recently, induced
pluripotent stem cell (iPSC) technology have shown that it
is possible for a fully differentiated cell to revert back to a
pluripotent state, a process called nuclear reprogramming
[2-7]. Moreover, it has become clear that not only is it
possible for the marble to travel up-slope but it can also
jump from valley to valley, a mechanism known as direct
lineage reprogramming. In this process, overexpression
of various factors can alter cellular identity from one
differentiated state into another. Focusing on the central
nervous system (CNS), we specifically review and discuss
recent progress made in directing the lineage reprogram-
ming of differentiated cells into neurons.
As a gateway for both cell replacement therapy and in vitro
disease modeling, direct lineage reprogramming of
differentiated cells has the potential to provide a large
number of patient-derived, class-specific neurons [8]. To
this end, directed differentiation of iPSCs also remains
promising; however, there are key differences to consider.
Reports demonstrate that nuclear reprogramming to an
iPSC state involves a transient tumorigenic pluripotent
state that is also susceptible to chromosomal aberrations
[9,10]. These concerns are less likely to apply to direct
reprogramming of differentiated cells. Additionally,
because direct reprogramming has been achieved between
different cell types, it is reasonable to postulate that a
terminal, new cell state may be more readily achieved
when the starting population shares some common
features or the same developmental origin. Direct line-
age reprogramming, of course, comes at a price, since
compared with the near-full erasure of epigenetic memory
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during the process of generating iPSCs (and their cell
derivatives), neurons obtained by direct lineage
reprogramming often maintain transcriptional and epige-
netic traces (a “memory”) of the cell of origin [11]. Finally,
while iPSC generation and differentiation occurs in vitro,
recent progress in direct lineage reprogramming indicates
that this process could be induced in vivo, bypassing
the need to transplant the end product [12-14]. For these
reasons, there is great interest in pursuing this avenue as an
alternative to iPSC directed differentiation.
Direct lineage conversion into neurons
One of the first studies to show that direct reprogramming
is feasible in the CNS employed astrocytes of the cerebral
cortex as the starting cell type. Overexpression of Pax6was
sufficient to reprogram early postnatal GFAP+ astrocytes to
Tuj1+ neurons [15]. Further characterization and improve-
ments from the Götz and Berninger groups have subse-
quently successfully produced electrophysiologically
active glutamatergic and GABAergic neurons from astro-
cytes, in vitro [15-18]. In addition, endogenous astrocytes
have been directly reprogrammed to neuroblasts and
neurons upon injury combined with Olig2 repression or
via overexpression of the BAM factors (AsclI, Brn2 and
Mytl1), respectively [14,19]. These astrocyte-to-neuron
studies underscore how minimal manipulation of tran-
scription factor signaling may be sufficient to directly
reprogram the identity of differentiated cells of the CNS
into neurons.
Collecting a large amount of astrocytes is not always
feasible, especially fromhumans. Thus, several groups have
focused on reprogrammingmore lineage-distant, yet easily
obtainable, skin fibroblasts into neurons. In 2010, the
Wernig group first demonstrated that transduction of three
genes – Ascl1, Brn2, and Mytl1 (BAM) – was sufficient to
directly reprogram primary postnatal mouse fibro-
blasts into induced neurons [20] (Fig. 1). These induced
neurons were electrophysiologically active, formed
synapses in vitro, and expressed markers of postmitotic
neurons. Subsequent studies have shown that induced
neurons can be made from human fibroblasts, with
different combinations of neuronal developmental genes,
miRNAs, small molecule inhibitors, and inhibition of a
splicing factor [21-25]. Remarkably, the Brüstle group has
attained a conversion yield of 200% (twoneurons for every
fibroblast plated) [26]. Since then, direct lineage repro-
gramming of induced neurons has been achieved from
other cell types, including pericytes and, notably, from
terminally differentiated cells of a different embryonic
lineage, like hepatocytes [27,28]. Given that neurons are
highly specialized, these groundbreaking studies under-
score the vast potential of direct lineage reprogramming to
generate even complex cell types.
These exciting results have now paved the way for the
ultimate challenge of generating specific classes of
neurons to recreate the heterogeneity of neurons resident
in the mammalian brain and to meet the need for
replacement of different classes of neurons in distinct
diseases.
In order to produce differentiated neurons that are
specifically lost in neurodegenerative disorders like
Amyotrophic Lateral Sclerosis, Parkinson’s disease, and
Alzheimer’s disease, several groups have added additional
factors to the original BAM cocktail. Mouse and human
fibroblasts have been directly reprogrammed into neu-
rons that resemble midbrain dopaminergic neurons, a
population that degenerates in Parkinson’s disease
Figure 1. Direct lineage reprogramming of somatic cells into
neurons
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[11,29-31]. The resulting neurons display electrophysio-
logical properties and share somemarkers of endogenous
dopaminergic neurons. Interestingly, the Jaenisch group
has shown that upon ectopic transplantation in the
striatum, these induced-dopaminergic neurons are able to
at least partly integrate into the local circuitry and produce
dopamine [29]. Similarly, the Eggan group successfully
reprogrammed mouse and human fibroblasts directly
into lower motor neurons [32]. Not only were these
neurons electrophysiologically active and expressed fewer
motor neuron-specific markers but they also integrated
into the ventral horn of the developing chick spinal cord
upon transplantation. As demonstrated in these studies,
the generation of neurons carrying defined, class-specific
features might be feasible and especially valuable in the
context of disease-related research and therapy.
While these results are encouraging, an important ques-
tion remains: do the induced neurons need to be
functionally and molecularly exact for direct application?
This young field is still struggling to define a set of
guidelines and standards that could be applicable across
experiments to classify cell types generated by direct
reprogramming. Global gene expression analysis of
induced-dopaminergic neurons and lower motor neurons
reveals a cell type that resembles the endogenous
population; however, it is also clear that it is not a perfect
match [11,28,32]. While functionality – i.e. firing proper-
ties, neurotransmitter release, appropriate connectivity –
may be enough for cell replacement therapy, perfectly
matched global gene expression profiles may be necessary
for reliable disease modeling. These two applications may
require separate criteria to define and accept the cell
population obtained by direct lineage reprogramming.
Similarly, the extent of neuronal-specificity required to
properly model a disease in vitro is disease-dependent. For
example, Parkinson’s disease primarily affects dopaminer-
gic neurons of the substantia nigra pars compacta, while
damages to the dopaminergic neurons of the ventral
tegmental area are variable [33]. Thus, for the purpose of
in vitrodiseasemodeling of Parkinson’s disease, itmight be
more useful to directly reprogram fibroblasts from
patients with a familial form of Parkinson’s disease into
specific dopaminergic neuron classes – those that resem-
ble more closely the neurons of the substantia nigra pars
compacta. Different criteria may apply to Alzheimer’s
disease, a disease in which many neuronal subtypes of the
cerebral cortex are affected [34]. In support of this
assessment, Qiang et al. isolated fibroblast samples from
human patients with Alzheimer’s disease and directly
reprogrammed them into a heterogeneous population of
neurons [35].While the resulting induced neurons did not
appear to be of any specific class, they still recapitulated
some of the cellular phenotypes observed in neurons of
Alzheimer’s disease patients that were absent in fibro-
blasts. While the jury is clearly still out and classification
criteria for reprogrammed cells are not well defined, it is
clear that such guidelines are needed for the field to move
forward.
In the context of neurological disorders, one theoretically
plausible idea to repair the brain would be to switch a
healthy neighboring neuronal subtype into neuronal
classes that are lost in disease, using direct reprogramming
in vivo, rather than in the dish. Neurons have historically
been thought to be immutable, and reversal of their
differentiated state impossible. However, nuclear repro-
gramming studies of olfactory and cortical neurons have
shown that even postmitotic neurons from postnatal mice
retain nuclear plasticity, as demonstrated in mice by
successful generation of pluripotent stem cells via tetra-
ploid complementation with the nucleus of a postmitotic
neuron [36-39]. In agreement with this, we have recently
demonstrated that it is possible to directly reprogram one
neuronal subtype of the cerebral cortex into another by
overexpression of a single transcription factor, Fezf2, in vivo
[13]. As a master regulator of corticospinal motor neuron
generation during development [40,41], Fezf2 induced
layer II/III callosal projection neurons to acquire the
molecular identity and axonal connectivity of layer V
corticospinal motor neuron. When expressed in cortical
neurons of layer IV, Fezf2 was also able to change their
electrophysiological properties to resemble those of
corticospinal motor neurons [12]. Although lineage
conversion was only possible during a defined window
of embryonic and postnatal life of the neurons, taken
together, these studies highlight not only the possibility
of in vivo direct lineage programming of neurons but also
the importance of knowledge gained from developmental
studies to inform de novo differentiation of specific
neuronal subtypes.
Future directions
Direct lineage reprogramming in the CNS is a concept in
its infancy. However, results from the last few years
clearly show that this is a field with great potential, both
for disease modeling and cell replacement therapy. In the
upcoming years, it will be necessary to further our
mechanistic understanding of the complex process by
which differentiated cells can “change their mind”. This
knowledge will be necessary to equip researchers with
additional molecular tools that facilitate the production
of neurons that meet the standards and needs of
transplantation, disease modeling, and chemical screen-
ing. At the cellular level, it will be important to define the
discrete steps of reprogramming and whether intermedi-
ate, stable cell states do exist. Initial data show that direct
lineage reprogramming to induced neurons is a direct
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process [32,35]. However, it is also conceivable that
intermediate cell types are present, but are difficult to
identify due to their expression of “unexpected” mole-
cular markers. Support for this hypothesis exists from
one of the rare events of natural reprogramming that
occurs during Caenorhabditis elegans development. Here,
natural direct reprogramming of rectal cells into motor
neurons does occur and it includes a discrete inter-
mediate cell type that does not express markers of either
rectal cells or motor neurons [42,43]. Tools have recently
become available for complex molecular profiling of
small populations of cells, often down to the single-cell
level. These new approaches will facilitate work to shed
light on the dynamics of direct lineage reprogramming.
Although multiple challenges and questions remain in
order to apply direct reprogramming to therapy, these
pioneering studies have paved the way for further
breakthroughs in what is an exciting and rapidly growing
field.
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